Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Insider Sells $3,137,953.04 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) insider John Paolini sold 58,424 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the transaction, the insider owned 65,623 shares in the company, valued at $3,524,611.33. This represents a 47.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $56.93 on Friday. The company’s 50 day simple moving average is $47.06 and its 200 day simple moving average is $43.59. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $24.85 and a fifty-two week high of $58.26. The firm has a market capitalization of $4.36 billion, a P/E ratio of 63.26 and a beta of 0.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business had revenue of $214.27 million for the quarter, compared to analyst estimates of $206.11 million. During the same period in the prior year, the business posted $0.11 earnings per share. Kiniksa Pharmaceuticals International’s revenue was up 55.5% compared to the same quarter last year. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several large investors have recently bought and sold shares of KNSA. Qube Research & Technologies Ltd increased its stake in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after purchasing an additional 653,236 shares in the last quarter. Rubric Capital Management LP increased its position in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after acquiring an additional 526,567 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after acquiring an additional 447,536 shares in the last quarter. Spruce Street Capital LP bought a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth $17,943,000. Finally, SG Americas Securities LLC increased its position in shares of Kiniksa Pharmaceuticals International by 288.6% during the fourth quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock worth $22,333,000 after acquiring an additional 402,078 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Jefferies Financial Group upped their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Canaccord Genuity Group upped their target price on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday. Finally, Citigroup upped their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $60.86.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.